产品概述
| 产品名称(Product Name) | Ret (phospho Tyr1015) Rabbit Polyclonal Antibody |
| 描述(Description) | Rabbit Polyclonal Antibody |
| 宿主(Host) | Rabbit |
| 应用(Application) | WB,IHC-P |
| 种属反应性(Reactivity) | Human,Mouse,Rat,Monkey |
产品性能
| 偶联物(Conjugation) | Unconjugated |
| 修饰(Modification) | Phospho Antibody |
| 同种型(Isotype) | IgG |
| 克隆(Clonality) | Polyclonal |
| 形式(Form) | Liquid |
| 存放说明(Storage) | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| 储存溶液(Buffer) | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% New type preservative N. |
| 纯化方式(Purification) | Affinity purification |
免疫原
| 基因名(Gene Name) | RET |
| 别名(Alternative Names) | RET; CDHF12; CDHR16; PTC; RET51; Proto-oncogene tyrosine-protein kinase receptor Ret; Cadherin family member 12; Proto-oncogene c-Ret |
| 基因ID(Gene ID) | 5979 |
| 蛋白ID(SwissProt ID) | P07949 |
产品应用
| 稀释比(Dilution Ratio) | WB 1:500-2000, IHC-P 1:50-300 |
| 蛋白分子量(Molecular Weight) | 124kDa |
研究背景
ret proto-oncogene(RET) Homo sapiens This gene, a member of the cadherin superfamily, encodes one of the receptor tyrosine kinases, which are cell-surface molecules that transduce signals for cell growth and differentiation. This gene plays a crucial role in neural crest development, and it can undergo oncogenic activation in vivo and in vitro by cytogenetic rearrangement. Mutations in this gene are associated with the disorders multiple endocrine neoplasia, type IIA, multiple endocrine neoplasia, type IIB, Hirschsprung disease, and medullary thyroid carcinoma. Two transcript variants encoding different isoforms have been found for this gene. Additional transcript variants have been described but their biological validity has not been confirmed. [provided by RefSeq, Jul 2008],catalytic activity:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.,disease:Chromosomal aberrations involving RET are a cause of thyroid papillary carcinoma (PACT) [MIM:188550]. Inversion inv(10)(q11.2;q21) generates the RET/CCDC6 (PTC1) oncogene; inversion inv(10)(q11.2;q11.2) generates the RET/NCOA4 (PTC3) oncogene; translocation t(10;14)(q11;q32) with GOLGA5 generates the RET/GOLGA5 (PTC5) oncogene; translocation t(8;10)(p21.3;q11.2) with PCM1 generates the PCM1/RET fusion; translocation t(6;10)(p21.3;q11.2) with RFP generates the Delta RFP/RET oncogene; translocation t(1;10)(p13;q11) with TRIM33 generates the TRIM33/RET (PTC7) oncogene; translocation t(7;10)(q32;q11) with TIF1 generates the TIF1/RET (PTC6) oncogene. The PTC5 oncogene has been found in 2 cases of PACT in children exposed to radioactive fallout after Chernobyl.,disease:Defects in RET are a cause of congenital central hypoventilation syndrome (CCHS) [MIM:209880]; also known as congenital failure of autonomic control or Ondine curse. CCHS is a rare disorder characterized by abnormal control of respiration in the absence of neuromuscular or lung disease, or an identifiable brain stem lesion. A deficiency in autonomic control of respiration results in inadequate or negligible ventilatory and arousal responses to hypercapnia and hypoxemia.,disease:Defects in RET are a cause of Hirschsprung disease (HSCR) [MIM:142623]. HSCR is a genetic disorder of neural crest development characterized by the absence of intramural ganglion cells in the hindgut, often resulting in intestinal obstruction. Occasionally, MEN2A or FMTC occur in association with HSCR.,disease:Defects in RET are a cause of pheochromocytoma [MIM:171300]. The pheochromocytomas are catecholamine-producing, chromaffin tumors that arise in the adrenal medulla in 90% of cases. In the remaining 10% of cases, they develop in extra-adrenal sympathetic ganglia and may be referred to as "paraganglioma." Pheochromocytoma usually presents with hypertension. Approximately 10% of pheochromocytoma is hereditary. The genetic basis for most cases of non-syndromic familial pheochromocytoma is unknown.,disease:Defects in RET are a cause of renal adysplasia [MIM:191830]; also known as renal agenesis or renal aplasia. Renal agenesis refers to the absence of one (unilateral) or both (bilateral) kidneys at birth. Bilateral renal agenesis belongs to a group of perinatally lethal renal diseases, including severe bilateral renal dysplasia, unilateral renal agenesis with contralateral dysplasia and severe obstructive uropathy.,disease:Defects in RET are the cause of medullary thyroid carcinoma (MTC) [MIM:155240]. MTC is a rare tumor derived from the C cells of the thyroid. Three hereditary forms are known, that are transmitted in an autosomal dominant fashion: (a) multiple neoplasia type 2A (MEN2A), (b) multiple neoplasia type IIB (MEN2B) and (c) familial MTC (FMTC), which occurs in 25-30% of MTC cases and where MTC is the only clinical manifestation.,disease:Defects in RET are the cause of multiple neoplasia type 2A (MEN2A) [MIM:171400]; also called multiple neoplasia type 2 (MEN2). MEN2A, the most frequent form of MTC, is an inherited cancer syndrome characterized by MTC, phaeochromocytoma and/or hyperparathyroidism.,disease:Defects in RET are the cause of multiple neoplasia type 2B (MEN2B) [MIM:162300]. MEN2B is an uncommon inherited cancer syndrome characterized by predisposition to MTC and phaeochromocytoma which is associated with marfanoid habitus, mucosal neuromas, skeletal and ophtalmic abnormalities, and ganglioneuromas of the intestine tract. Then the disease progresses rapidly with the development of metastatic MTC and a pheochromocytome in 50% of cases.,disease:Defects in RET may be a cause of colorectal cancer (CRC) [MIM:114500].,function:Probable receptor with tyrosine-protein kinase activity; important for development.,polymorphism:The Cys-982 polymorphism may be associated with an increased risk for developing Hirschsprung disease.,PTM:Autophosphorylated on C-terminal tyrosine residues upon ligand stimulation.,PTM:Phosphorylated.,similarity:Belongs to the protein kinase superfamily. Tyr protein kinase family.,similarity:Contains 1 cadherin domain.,similarity:Contains 1 protein kinase domain.,subunit:Phosphorylated form interacts with the PBT domain of DOK2, DOK4 and DOK5.,
研究领域
Endocytosis;Pathways in cancer;Thyroid cancer;
关键字: RET;Ret;(phospho;Tyr1015);Rabbit;Polyclonal;Antibody;一抗
武汉恩玑生命科技有限公司(EnkiLife)是一家深耕生命科学,专注细胞生物学和免疫学科研试剂的研发、生产与销售的生物技术企业,在全球100多个国家和地区开展业务,致力于为科研工作者提供高质量的产品和卓越的客户服务,推动生命科学的发展。
EnkiLife的产品线涵盖细胞系、原代细胞、细胞培养基、血清、细胞检测试剂盒、重组靶点蛋白、细胞因子、重组抗体、ELISA试剂盒、生化试剂盒等,并提供技术服务与定制开发,覆盖了生命科学研究的各大关键领域,包括细胞生物学、癌症、免疫学、神经科学、心血管疾病、干细胞、表观遗传学、内分泌、蛋白质组学、代谢组学等,全方位满足您的实验需求,让您享受科研的乐趣!
公司现已建立四大技术平台:
EnCyto?细胞培养及检测平台:拥有细胞系库(500+)、原代细胞库(500+)、基础培养基和完全培养基(1200+)
EnkiPro?重组蛋白平台:现货产品2000+,可提供定制化表达服务
EnAb?重组抗体平台:重组兔单抗(3000+),可提供定制化和标记服务
EnKits?试剂盒开发平台:可提供优质的ELISA试剂盒、配套试剂、抗体对、生化试剂盒等相关产品
EnkiLife在生产管理方面引入ISO9001质量管理体系和信息化、自动化的管理工具,拥有高效稳定的交付能力,与全球知名品牌建立了紧密的合作。
EnkiLife始终坚持以技术创新为驱动,以匠心铸就品质,以品质服务客户。
我们期待与更多的全球科研工作者和企业携手合作,共同推动生命科学领域的进步与发展。